3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Blast Crisis
2
Retroperitoneal liposarcoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Mastocytosis, Systemic
1
Liposarcoma
1
Leukemia
1
Leiomyosarcoma
1
Hypereosinophilic Syndrome
1
Chondrosarcoma
1
Interventions
venetoclax
5
Dexamethasone
5
Cytarabine
3
Cyclophosphamide
3
Vincristine
2
Decitabine
2
trametinib
1
ruxolitinib
1
pegaspargase
1
nilotinib
1
navitoclax
1
merphos
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
capivasertib
1
blinatumomab
1
Vorinostat
1
Spinal Puncture
1
Specimen Handling
1
Mitoxantrone
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
Dasatinib
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
×
nilotinib
×
Clear all
NCT00905398
2015-07-09
ALLPhi
Universidade Federal do Rio de Janeiro
Phase 1/2
Terminated
8 enrolled